secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABVC BIOPHARMA, INC. (ABVC)
CIK:        0001173313
Form:       8-K
Filed at:   2024-04-17T23:59:59+00:00
Accession:  0001213900-24-033598
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ABVC signs exclusive license deal with OncoX for NSCLC drug; up to $13.75M in fees + up to $12.5M royalties
--------------------------------------------------------------------------------

- License for ABVC's single-herb botanical extract from Maitake Mushroom (BLEX 404) for NSCLC in North America for 20 years.
- Aggregate license fee of $12.5M (cash or OncoX shares) due within 30 days of signing; additional $1.25M milestone after OncoX's next fundraising (no guarantee).
- ABVC and affiliate Rgene also entitled to 5% royalties on net sales, capped at $12.5M, post-commercial launch.
- FDA has approved IND for ABV-1519 (BLEX 404) as combination therapy with chemotherapy for NSCLC.
- OncoX is a private BVI company specializing in oncology dietary supplements; deal leverages ABVC's clinical-stage pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173313/000121390024033598/0001213900-24-033598-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173313/000121390024033598/ea0203971-8k_abvcbio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-033598

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer